Brazikumab ( AMG139, initially known as AMG139) is a key therapeutic drug targeting interleukin-17F . Recent trial results from the pivotal NYMPH3 trial evaluating its efficacy in patients with https://ianglee901122.mpeblog.com/75333533/brazikumab-amg139-recent-developments-and-trial-outcomes